Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-20T18:35:15.596Z Has data issue: false hasContentIssue false

1431 – Effect Of Cigarette Smoking In Male Patients With Schizophrenia Treated With Olanzapine

Published online by Cambridge University Press:  15 April 2020

N. Zivkovic
Affiliation:
Clinic for Psychiatric Diseases ‘Dr Laza Lazarevic’
G. Djokic
Affiliation:
Clinic for Psychiatric Diseases ‘Dr Laza Lazarevic’
B. Bajovic
Affiliation:
Clinic for Psychiatric Diseases ‘Dr Laza Lazarevic’
K. Zoric
Affiliation:
Clinic for Psychiatric Diseases ‘Dr Laza Lazarevic’
J. Lekovic
Affiliation:
Medical Faculty University of Belgrade, Belgrade, Serbia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Patients with schizophrenia have elevated rates of cigarette smoking, and difficulty in smoking cessation. Cigarette smoking may reduce plasma levels of antipsychotics up to 50%.

Objective

To investigate effects of cigarette smoking in olanzapine treatment of schizophrenia.

Methods

91 patients with schizophrenia, aged 18-51, were divided into four groups. Control group (25 patients) and experimental groups: E1, 1-20 cigarettes/24h (23 patients), E2, 21-40 cigarettes/24h (22 patients) and E3, 40+ cigarettes/24h (21 patients). Patients were observed for one year period. Patients were assessed by Positive and Negative Symptom Schedule Scale (PANSS) at baseline and after one year.

Results

No significant differences were found for PANSS score at baseline (p = 0.535). PANSS reduction at study endpoint was significant in all groups (p < 0.001). PANSS reduction was highest in non-smokers group 65.5%, and lowest in group of heavy smokers (40+ cigarettes/24h) 39.2%. There is a statistically significant difference in PANSS reduction between nonsmokers group and all smokers groups (p < 0.001). There is a statistically significant difference in PANSS reduction between E1 and E2, and E1 and E3 group (p < 0.001), and no difference between E2 and E3 group (p = 0.414). There is a statistically significant difference in olanzapine average daily dose after one year between non-smokers group and all smokers groups (p < 0.001).

Conclusions

Olanzapine therapy is most efficient in non-smokers group. Smoking more than 20 cigarettes per day significantly reduces effects of olanzapine therapy. Average daily dose of olanzapine is significantly lower in non-smokers group than in all three groups of smokers.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.